Production (Stage)
Adaptimmune Therapeutics plc
ADAP
$0.2801
$0.00572.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 878.53% | 195.34% | 146.27% | 99.90% | -74.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 878.53% | 195.34% | 146.27% | 99.90% | -74.21% |
| Cost of Revenue | 5.50% | 17.88% | -35.23% | -19.97% | -27.58% |
| Gross Profit | 130.54% | 143.64% | 121.26% | 95.38% | -0.83% |
| SG&A Expenses | 38.23% | 46.80% | 9.17% | 0.13% | 11.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.13% | 27.23% | 18.13% | 19.86% | 14.96% |
| Operating Income | 70.23% | 52.81% | 65.38% | 33.87% | -75.83% |
| Income Before Tax | 59.14% | 40.25% | 53.06% | 19.14% | -45.23% |
| Income Tax Expenses | 193.05% | 167.66% | -58.91% | -59.86% | -50.28% |
| Earnings from Continuing Operations | 57.23% | 37.81% | 53.24% | 20.35% | -43.15% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 57.23% | 37.81% | 53.24% | 20.35% | -43.15% |
| EBIT | 70.23% | 52.81% | 65.38% | 33.87% | -75.83% |
| EBITDA | 74.66% | 58.44% | 73.68% | 40.69% | -76.13% |
| EPS Basic | 62.68% | 44.94% | 57.40% | 36.98% | -3.71% |
| Normalized Basic EPS | 73.32% | 57.99% | 68.43% | 49.05% | -26.83% |
| EPS Diluted | 55.93% | 35.70% | 51.29% | 31.61% | -4.30% |
| Normalized Diluted EPS | 72.76% | 57.22% | 67.63% | 48.32% | -26.77% |
| Average Basic Shares Outstanding | 16.40% | 25.62% | 32.42% | 40.35% | 34.70% |
| Average Diluted Shares Outstanding | 16.89% | 25.92% | 32.73% | 40.67% | 34.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |